Trials / Unknown
UnknownNCT01066689
Impact of Treatment With Rituximab on the Progression of Humoral Acute Rejection After Renal Transplantation
Phase III Study of Impact of Treatment With Rituximab on the Progression of Humoral Acute Rejection After Renal Transplantation.
- Status
- Unknown
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 64 (estimated)
- Sponsor
- University Hospital, Tours · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
Assessing the impact of J12 curative treatment with rituximab (375 mg / m² on J5) based on a composite "TREATMENT FAILURE"
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | MabThera | MabThera 500mg/50ml I.V. infusion, single dose : 375 mg/m2 |
| DRUG | Physiological serum (Sodium Chloride, sodium citrate) | Solution for I.V. infusion Sodium Chloride (pH 6.5), polysorbate 80, sodium citrate (10.0mg/ml) |
Timeline
- Start date
- 2008-10-01
- Primary completion
- 2011-10-01
- Completion
- 2011-10-01
- First posted
- 2010-02-10
- Last updated
- 2010-02-10
Locations
32 sites across 1 country: France
Source: ClinicalTrials.gov record NCT01066689. Inclusion in this directory is not an endorsement.